- Home
- TNGX vs BRDG Comparison
TNGX vs BRDG Comparison
Compare TNGX & BRDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- BRDG
- Stock Information
- Founded
- TNGX 2014
- BRDG 2009
- Country
- TNGX United States
- BRDG United States
- Employees
- TNGX N/A
- BRDG N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- BRDG Investment Managers
- Sector
- TNGX Health Care
- BRDG Finance
- Exchange
- TNGX Nasdaq
- BRDG Nasdaq
- Market Cap
- TNGX 351.2M
- BRDG 445.0M
- IPO Year
- TNGX N/A
- BRDG 2021
- Fundamental
- Price
- TNGX $6.73
- BRDG $10.71
- Analyst Decision
- TNGX Strong Buy
- BRDG Hold
- Analyst Count
- TNGX 6
- BRDG 5
- Target Price
- TNGX $12.20
- BRDG $11.30
- AVG Volume (30 Days)
- TNGX 2.5M
- BRDG 651.9K
- Earning Date
- TNGX 08-06-2025
- BRDG 08-05-2025
- Dividend Yield
- TNGX N/A
- BRDG 3.81%
- EPS Growth
- TNGX N/A
- BRDG N/A
- EPS
- TNGX N/A
- BRDG N/A
- Revenue
- TNGX $40,990,000.00
- BRDG $453,729,000.00
- Revenue This Year
- TNGX N/A
- BRDG N/A
- Revenue Next Year
- TNGX N/A
- BRDG $36.21
- P/E Ratio
- TNGX N/A
- BRDG N/A
- Revenue Growth
- TNGX 10.09
- BRDG 39.05
- 52 Week Low
- TNGX $1.03
- BRDG $7.09
- 52 Week High
- TNGX $12.02
- BRDG $11.69
- Technical
- Relative Strength Index (RSI)
- TNGX 75.80
- BRDG 69.39
- Support Level
- TNGX $5.75
- BRDG $10.27
- Resistance Level
- TNGX $6.40
- BRDG $10.51
- Average True Range (ATR)
- TNGX 0.47
- BRDG 0.23
- MACD
- TNGX 0.02
- BRDG 0.07
- Stochastic Oscillator
- TNGX 89.51
- BRDG 87.72
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.